TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18324427
Drug: Caspofungin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin therapy as empirical therapy (ET)
Study: 18324427
Drug: Caspofungin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin therapy
Study: 7755939
Drug: Felodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (5 to 20 mg; n = 13)
Study: 7755939
Drug: Ramipril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (2.5 to 10 mg; n = 15)
Study: 2274600
Drug: Propranolol (20-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (20-80 mg bid)
Study: 2274600
Drug: Clonidine (0.1-0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.1-0.3 mg bid)
Study: 2274600
Drug: Propranolol (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (20-40 mg bid)
Study: 30924254
Drug: 3-in-1 night
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-in-1 night facial serum (NFS) containing melatonin, bakuchiol, and ascorbyl tetraisopalmitate, applied once daily for 12 weeks
Study: 24501946
Drug: Itopride (IG)
Normalized name: IG
DrugBank: Itopride (DB04924)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itopride (IG) 50 mg 3 times a day (tid)
Study: 24501946
Drug: Domperidone (DP)
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (DP) 10 mg tid
Study: 21626121
Drug: Betahistine dihydrochloride
Normalized name: Betahistine Dihydrochloride
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine dihydrochloride 288-480 mg/day
Study: 10842890
Drug: Randomized clinical
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized clinical trial design measuring drug activity on acute parameters.
Study: 9314427
Drug: Isradipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (2.5 to 10 mg BID) on high-salt diet
Study: 9314427
Drug: Isradipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (2.5 to 10 mg BID) on low-salt diet
Study: 3524465
Drug: Immunochemotherapy (L-I-C)
Normalized name: C.I. acid blue 324
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunochemotherapy (L-I-C)
Study: 3524465
Drug: Post-operative chemotherapy
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative chemotherapy (L-I-C)
Study: 3524465
Drug: Long-term continuous
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term continuous chemotherapy (L-C-C)
Study: 3524465
Drug: Long-term continuous
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term continuous chemotherapy (L-C-C) with CQ+CPA+ADM+5-FU
Study: 3524465
Drug: Post-operative radiation
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative radiation therapy
Study: 3524465
Drug: Immunotherapy combined
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy combined with radiation therapy
Study: 3524465
Drug: Bronchial arterial
Normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bronchial arterial infusion (BAI)
Study: 3524465
Drug: Short-term chemotherapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term chemotherapy (S-C)
Study: 3524465
Drug: Long-term intermittent
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term intermittent chemotherapy (L-I-C)
Study: 15761945
Drug: Albuterol dry
Normalized name: albuterol Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol dry powder inhalers with fine particle doses (FPDs) of 100 microg
Study: 15761945
Drug: Albuterol dry
Normalized name: albuterol Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol dry powder inhalers with fine particle doses (FPDs) of 120 microg
Study: 15761945
Drug: Albuterol dry
Normalized name: albuterol Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol dry powder inhalers with fine particle doses (FPDs) of 160 microg
Study: 15761945
Drug: Albuterol dry
Normalized name: albuterol Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol dry powder inhalers
Study: 12649515
Drug: Triflusal (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal (600 mg/d)
Study: 10357343
Drug: Granisetron 3
Normalized name: granisetron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 3 mg plus dexamethasone 8 mg
Study: 2802477
Drug: Endoscopic dilatation
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic dilatation and antireflux medication
Study: 990784
Drug: Naloxone 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 40 mug administered intravenously one minute after birth
Study: 29474712
Drug: Average on-treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Average on-treatment SBP ≤130 mmHg
Study: 29474712
Drug: Average on-treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Average on-treatment SBP between 131 and 141 mmHg
Study: 29474712
Drug: Average on-treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Average on-treatment SBP ≥142 mmHg
Study: 23328286
Drug: 30 ml/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml/d lactulose
Study: 23328286
Drug: 60 ml/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 ml/d lactulose
Study: 23328286
Drug: 90 ml/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 ml/d lactulose
Study: 20131262
Drug: LY2439821 (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2439821 (0.2 mg/kg)
Study: 20131262
Drug: LY2439821 (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2439821 (2.0 mg/kg)
Study: 20131262
Drug: LY2439821 (0.2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2439821 (0.2, 0.6, or 2.0 mg/kg)
Study: 8746882
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg estradiol-valerat (E2V) and 10 mg dydrogesterone for 10 months
Study: 2143712
Drug: d‐fenfluramine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐fenfluramine (30 mg daily)
Study: 2143712
Drug: placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo plus low‐calorie diet (1500‐1200 kcal daily)
Study: 26170041
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D and leucine-enriched whey protein nutritional supplement
Study: 24021479
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance tests (OGTTs) and waist measurement
Study: 17578485
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Pramipexole 0.5 mg and Domperidone 40 mg
Study: 11037740
Drug: 5-isosorbide-mononitrate (5-ISMN)
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-isosorbide-mononitrate (5-ISMN) 30 mg administered orally three times daily for 4 weeks
Study: 9265038
Drug: TX 1341
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TX 1341 (3 chewable lactate and citrate of magnesium tablets, each containing 120 mg of magnesium-element)
Study: 9265038
Drug: Reference magnesium
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference magnesium (MAG2, 3 drinkable ampoules of pidolate of magnesium, each containing 122 mg of magnesium-element)
Study: 27326985
Drug: Cetirizine, fexofenadine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine, fexofenadine, bilastine, desloratadine, or ebastine (daily oral dose for 8 weeks)
Study: 27326985
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of antihistamine after 4 weeks for non-responders
Study: 27326985
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antihistamine treatment)
Study: 24736647
Drug: 1.4 g
Normalized name: MENTHOL 1.4 g in 100 g TOPICAL CREAM [Cetilar]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4 g of EPA+DHA daily oil capsule supplements (n=24)
Study: 12613519
Drug: Anthracycline treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline treatment with average dose of 174 mg/m2 (median 200 mg/m2) and mediastinum irradiation dose of 21 Gy (median 30 Gy)
Study: 9750444
Drug: 7 g
Normalized name: Vaporizer 1.7 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g of tranexamic acid after induction of anesthesia and 3 g after CPB (group T)
Study: 7625419
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg for 2 years
Study: 354736
Drug: Conventional bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional bowel preparation (CBP) using oral magnesium sulphate, enemas and rectal washouts
Study: 354736
Drug: Oral neomycin
Normalized name: neomycin Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral neomycin and metronidazole for 48 h before operation added to all three methods of bowel preparation
Study: 354736
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no bowel preparation)
Study: 31805256
Drug: Low-dose NL003
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose NL003
Study: 31805256
Drug: Middle-dose NL003
Normalized name: WHEAT MIDDLINGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle-dose NL003
Study: 31805256
Drug: High-dose NL003
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose NL003
Study: 29748353
Drug: Higher-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose edoxaban regimen (HD-ER)
Study: 29748353
Drug: Lower-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose edoxaban regimen
Study: 22267467
Drug: RBV dose
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RBV dose ≥3.0 g/kg
Study: 22267467
Drug: RBV dose
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RBV dose <3.0 g/kg
Study: 22267467
Drug: RBV dose
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RBV dose >3.0 g/kg
Study: 12392039
Drug: BiDil (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: BiDil (a fixed combination of hydralazine and isosorbide dinitrate)
Study: 19382124
Drug: 200 microl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microl lavender capsules
Study: 17498014
Drug: Standard preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preoperative preparation (Control)
Study: 11779724
Drug: Budesonide (1,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (1,600 microg/d) after initial treatment
Study: 21055142
Drug: felodipine 5
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: felodipine 5 mg q.d + irbesartan 150 mg q.d (F + I group, n = 49)
Study: 21055142
Drug: felodipine 5
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: felodipine 5 mg q.d + metoprolol 47.5 mg q.d (F + M group, n = 50)
Study: 31355286
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccination (4 doses)
Study: 31355286
Drug: Birth dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birth dose of Hepatitis B vaccine
Study: 11221809
Drug: Acarbose (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (300 mg/day)
Study: 24431911
Drug: Voglibose (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose (0.9 mg/day)
Study: 20307032
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone injection
Study: 20307032
Drug: Combined radial
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined radial optic neurotomy/intraocular triamcinolone injection
Study: 18559703
Drug: HGF plasmid
Approvals — FDA: no, EMA: no, PMDA: no
Description: HGF plasmid (high dose: 4.0 mg at days 0, 14, and 28)
Study: 18559703
Drug: HGF plasmid
Approvals — FDA: no, EMA: no, PMDA: no
Description: HGF plasmid (low dose: 0.4 mg at days 0, 14, and 28)
Study: 18559703
Drug: HGF plasmid
Approvals — FDA: no, EMA: no, PMDA: no
Description: HGF plasmid (middle dose: 4.0 mg at days 0 and 28)
Study: 7847516
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen (50 micrograms of estradiol daily) with levonorgestrel-releasing intrauterine device
Study: 7847516
Drug: Oral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estrogen (2 mg of estradiol valerate and 1 mg of norethisterone acetate daily)
Study: 7074558
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy of megestrol, cyclophosphamide, and doxorubicin (MCA)
Study: 7074558
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy of megestrol, cyclophosphamide, doxorubicin, and 5-fluorouracil (MCAF)
Study: 7074558
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy of megestrol, 1-phenylalanine mustard, and 5-fluorouracil (MLF)
Study: 31994751
Drug: Posterior-stabilized (PS)
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior-stabilized (PS) knee implant
Study: 31994751
Drug: Cruciate-retaining (CR)
Normalized name: Gentiana cruciata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cruciate-retaining (CR) knee implant
Study: 31994751
Drug: Medial-stabilized (MS)
Normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medial-stabilized (MS) knee implant
Study: 26310261
Drug: Intravenous elafin
Normalized name: Elafin
DrugBank: Elafin (DB05161)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous elafin 200 mg
Study: 24316098
Drug: Gastroretentive double-layered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastroretentive double-layered tablet formulation (GSS)
Study: 22724877
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate (220 mg capsules, three times daily until end of chemotherapy)
Study: 22724877
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three placebo capsules daily)
Study: 15175869
Drug: Preplanning based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preplanning based on pretherapeutic transrectal ultrasound for the first HDR brachytherapy implant.
Study: 15175869
Drug: Preplanning based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preplanning based on ultrasound from the first HDR brachytherapy implant for the second HDR brachytherapy.
Study: 15175869
Drug: Postplans compared
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postplans compared to preplans for both HDR brachytherapy implants.
Study: 11937460
Drug: Maximum medical
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum medical therapy
Study: 11475718
Drug: Weihuigui Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weihuigui Decoction (WHGD) 100 ml, three times a day for 2 weeks
Study: 6587757
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg thrice daily)
Study: 30897983
Drug: Dexpanthenol-containing ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexpanthenol-containing ointment
Study: 26841799
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (VALID programme)
Study: 9257738
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg three times daily from day -2 to day 2)
Study: 9257738
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g four times daily from day -2 to day 0)
Study: 9257738
Drug: Sparfloxacin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin alone (400 mg single oral dose on day 0)
Study: 8290678
Drug: Benztropine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benztropine (6 mg/day)
Study: 3579261
Drug: Erythromycin ethylsuccinate
Normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin ethylsuccinate (40 mg/kg per day) for 5 days
Study: 28033691
Drug: Memantine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (10 mg/day for week 1; 20 mg/day for weeks 2-6) plus olanzapine (15-20 mg/day)
Study: 22076437
Drug: Low to
Normalized name: Mutton Tallow Topical application Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low to moderate doses of lithium
Study: 20663600
Drug: Coronectomies with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coronectomies with endodontic treatments
Study: 20663600
Drug: Coronectomies without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coronectomies without endodontic treatment
Study: 17997267
Drug: Twice-weekly vouchers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly vouchers to reinforce abstinence and positive behaviors
Study: 16393332
Drug: Periodic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periodic administration of penicillin G and V (Group A)
Study: 16393332
Drug: No repeated
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No repeated penicillin administration (Group B)
Study: 1442478
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) infusion
Study: 4066373
Drug: Mitomycin instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin instillation therapy
Study: 4066373
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no mitomycin treatment)
Study: 22370004
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus a cognitive behaviour therapy (CBT) booklet (BUC)
Study: 22370004
Drug: Graded exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded exercise therapy (GET)
Study: 17956953
Drug: GH replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH replacement therapy (individualized dose titration regimen)
Study: 17956953
Drug: GH replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH replacement therapy (fixed body weight-based dosing regimen)
Study: 17956953
Drug: GH replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH replacement therapy (both dosing regimens combined)
Study: 16160131
Drug: High-dose radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radiation therapy (79.2 Gy)
Study: 16160131
Drug: Conventional-dose radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional-dose radiation therapy (70.2 Gy)
Study: 12100367
Drug: UFH (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFH (5000 IU subcutaneously thrice daily)
Study: 8555803
Drug: Levodopa and
Normalized name: levodopa and decarboxylase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa and dopa decarboxylase inhibitor (arm 1)
Study: 8555803
Drug: Levodopa and
Normalized name: levodopa and decarboxylase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa and decarboxylase inhibitor in combination with selegiline (arm 2)
Study: 2355103
Drug: labetalol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: labetalol (100 mg bid)
Study: 2355103
Drug: hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hydrochlorothiazide (HCTZ) (25 mg bid)
Study: 872445
Drug: Long-term diphenylhydantoin
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term diphenylhydantoin (DPH) treatment
Study: 872445
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of DPH treatment
Study: 28885425
Drug: 10-mL 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mL 1% lidocaine paracervical nerve block
Study: 25845406
Drug: Vagisan(®) Moisturising
Normalized name: Vagistat
DrugBank: Tioconazole (DB01007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vagisan(®) Moisturising Cream (CREAM)
Study: 25845406
Drug: Non-hormonal vaginal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-hormonal vaginal gel (GEL)
Study: 23273638
Drug: Tualang honey
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tualang honey (3 mls intraoperatively, followed by 4 mls orally three times daily for seven days) + Sultamicillin (25mg/kg IV three times daily for two days, then orally twice daily for five days)
Study: 23273638
Drug: Sultamicillin (25mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sultamicillin (25mg/kg IV for two days, then orally twice daily for five days)
Study: 20084368
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg MDMA
Study: 20084368
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg MDMA
Study: 16171020
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 25% metronidazole-containing mucoadhesive lipogel
Study: 12849803
Drug: Embryo selection
Normalized name: human embryo tissue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Embryo selection based on sequential evaluation of both pronuclear morphology and embryo morphology on day 3
Study: 10383498
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg, clarithromycin 500 mg, and amoxycillin 1000 mg (OAC)